Peer reviewed by medical experts that included three U.S.government senior scientists and published in the American Journal of Therapeutics,the research is the most comprehensive review of the available data taken from clinical,in vitro,animal,and real-world studies.Led by the Front Line COVID-19 Critical Care Alliance(FLCCC),a group of medical and scientific experts reviewed published peer-reviewed studies,manuscripts,expert meta-analyses,and epidemiological analyses of regions with ivermectin distribution efforts all showing that ivermectin is an effective prophylaxis and treatment for COVID-19.
这项研究是对现有临床、体外、动物和现实世界研究数据的最全面综述。在一线2019冠状病毒疾病重症监护联盟(FLCCC)的领导下，一组医学和科学专家审查了已发表的同行评议研究、手稿、专家荟萃分析，以及对伊维菌素分发地区的流行病学分析，所有这些都表明伊维菌素是一种有效的2019冠状病毒疾病预防和治疗方法。
"We did the work that the medical authorities failed to do,we conducted the most comprehensive review of the available data on ivermectin,"said Pierre Kory,M.P.A.,MD,president and chief medical officer of the FLCCC."We applied the gold standard to qualify the data reviewed before concluding that ivermectin can end this pandemic."
"我们做了医疗机构未能做到的工作，我们对伊维菌素的现有数据进行了最全面的审查,"FLCCC 主席兼首席医疗官、医学博士皮埃尔·科里(Pierre Kory)说。"在得出伊维菌素能够结束这场流行病的结论之前，我们采用了黄金标准对审查的数据进行了限定。"
A focus of the manuscript was on the 27 controlled trials available in January 2021,15 of which were randomized controlled trials(RCT's),the preferred trial of the World Health Organization,U.S.National Institutes of Health,and the European Medicines Agency.Consistent with numerous meta-analyses of ivermectin RCT's since published by expert panels from the UK,Italy,Spain,and Japan,they found large,statistically significant reduction in mortality,time to recovery and viral clearance in COVID-19 patients treated with ivermectin.
手稿的重点是2021年1月可用的27个对照试验，其中15个是随机对照试验，世界卫生组织、美国国立卫生研究院和欧洲药物管理局的首选试验。来自英国、意大利、西班牙和日本的专家小组发表了大量关于伊维菌素 RCT 的荟萃分析，他们发现使用伊维菌素治疗的2019冠状病毒疾病患者在死亡率、恢复时间和病毒清除率方面有显著的统计学意义下降。
To evaluate the efficacy of ivermectin in preventing COVID-19,3 RCT's and 5 observational controlled trials,including almost 2,500 patients all reported that ivermectin significantly reduces the risk of contracting COVID-19 when used regularly.
为了评估伊维菌素预防2019冠状病毒疾病的效果，3个 RCT 和5个观察对照试验，包括将近2500名患者都报告说，伊维菌素经常使用可以显著降低感染2019冠状病毒疾病的风险。
Many regions around the world now recognize that ivermectin is a powerful prophylaxis and treatment for COVID-19.South Africa,Zimbabwe,Slovakia,Czech Republic,Mexico,and now,India,have approved the drug for use by medical professionals.The results as seen in this latest study demonstrate that the ivermectin distribution campaigns repeatedly led to"rapid population-wide decreases in morbidity and mortality."
世界上许多地区现在认识到伊维菌素是一种强有力的2019冠状病毒疾病预防和治疗药物。南非、津巴布韦、斯洛伐克、捷克共和国、墨西哥以及现在的印度已经批准该药物供医疗专业人员使用。这项最新研究的结果表明，伊维菌素的分布运动反复导致"全人口的发病率和死亡率迅速下降"
"Our latest research shows,once again,that when the totality of the evidence is examined,there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19,"said Paul E.Marik,M.D.,FCCM,FCCP,founding member of the FLCCC and Chief,Pulmonary and Critical Care Medicine at Eastern Virginia Medical School."We can no longer rely on many of the larger health authorities to make an honest examination of the medical and scientific evidence.So,we are calling on regional public health authorities and medical professionals around the world to demand that ivermectin be included in their standard of care right away so we can end this pandemic once and for all."
我们最新的研究再一次表明，当所有的证据都得到检验时，毫无疑问，伊维菌素作为2019冠状病毒疾病的安全预防和治疗是非常有效的,"保罗 e.马里克，医学博士，FCCM，fpcp，FLCCC 的创始成员，东弗吉尼亚医学院肺病和危重病医学主任说。"我们不能再依赖许多较大的卫生当局对医学和科学证据进行诚实的检查。因此，我们呼吁世界各地的地区公共卫生当局和医疗专业人员要求立即将伊维菌素纳入他们的护理标准，以便我们能够一劳永逸地结束这场流行病。"
**Source
转自：
https://eraoflight.com/2021/09/22/trust-the-science-the-evidence-for-ivermectin-and-covid-19/
